Yves Piette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yves Piette has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Filip De Keyser
Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
3 shared publications - Karin Melsens
Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
3 shared publications - Vanessa Smith
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
3 shared publications - Amber Vanhaecke
Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
2 shared publications - Ellen Deschepper
Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
2 shared publications - Maurizio Cutolo
Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine (DiMI) University of Genova Genoa Italy
2 shared publications
Latest Publications
- 26 March 2020
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 38 (2) , 212-219
Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy
Full Papers; Authors: Y. Piette, M. De Sloovere, S. Vandendriessche, J. Dehoorne, J.L. De Bleecker, L. Van Praet, A.-S. Vander Mijnsbrugge, S. De Schepper, P. Jacques, F. De Keyser, V. Smith, C. Bonroy
- 26 March 2020
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 38 (2) , 212-219
Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy
Full Papers; Authors: Y. Piette, M. De Sloovere, S. Vandendriessche, J. Dehoorne, J.L. De Bleecker, L. Van Praet, A.-S. Vander Mijnsbrugge, S. De Schepper, P. Jacques, F. De Keyser, V. Smith, C. Bonroy
- 1 August 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (8) , 775-780
Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients
- 1 August 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (8) , 775-780
Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients
- 1 April 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (4) , 344-352
Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal
- 1 April 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (4) , 344-352
Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal
- 18 July 2016
- No. 5,p. 148-151
Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
The European Scleroderma Study Group (EScSG) activity index meets nearly all the OMERACT-standards of truth, discrimination and feasibility. The sensitivity to change remains to be attested. This study assesses sensitivity to change of the EScSG activity index in patients with early and severe diffuse cutaneous Systemic Sclerosis (dcSSc) treated with rituximab. 12-month follow-up (open-label study) of 14 consecutive patients with early dcSSc. Patients received an infusion of two times 1000 mg rituximab at month 0 and 6, together with 100 mg methylprednisolone. Clinical read outs (modified Rodnan skin score [mRSS], lung function and echocardiography) and EScSG activity index were performed at month 0, 3, 6 and 12. Mixed models analyses (MMA) were used to evaluate changes in parameters over time. There was a clinically significant change in skin score with a mean (SD) mRSS of 24.8 (4.44) at baseline and 10.4 (3.12) at month 12 (MMA p<0.001). Also the EScSG activity index decreased significantly, with a mean (SD) of 4.3 (1.79) at baseline and 0.7 (0.83) at month 12 (MMA p<0.001). The estimated mean change of the EScSG activity index was -3.6 (95%CI -4.9; -2.4) over 12 months. Indices of internal organ involvement remained stable throughout the study. A significant improvement of the EScSG activity index was observed, in line with the significant improvement of the mRSS and the stabilisation of internal organ involvement. To our knowledge, this is the first study to attest sensitivity to change of the EScSG activity index in the subset of 'early' dcSSc. ClinicalTrials.gov Registration, http://clinicaltrials.gov, number NCT00379431.
- 18 July 2016
- No. 5,p. 148-151
Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
The European Scleroderma Study Group (EScSG) activity index meets nearly all the OMERACT-standards of truth, discrimination and feasibility. The sensitivity to change remains to be attested. This study assesses sensitivity to change of the EScSG activity index in patients with early and severe diffuse cutaneous Systemic Sclerosis (dcSSc) treated with rituximab. 12-month follow-up (open-label study) of 14 consecutive patients with early dcSSc. Patients received an infusion of two times 1000 mg rituximab at month 0 and 6, together with 100 mg methylprednisolone. Clinical read outs (modified Rodnan skin score [mRSS], lung function and echocardiography) and EScSG activity index were performed at month 0, 3, 6 and 12. Mixed models analyses (MMA) were used to evaluate changes in parameters over time. There was a clinically significant change in skin score with a mean (SD) mRSS of 24.8 (4.44) at baseline and 10.4 (3.12) at month 12 (MMA p<0.001). Also the EScSG activity index decreased significantly, with a mean (SD) of 4.3 (1.79) at baseline and 0.7 (0.83) at month 12 (MMA p<0.001). The estimated mean change of the EScSG activity index was -3.6 (95%CI -4.9; -2.4) over 12 months. Indices of internal organ involvement remained stable throughout the study. A significant improvement of the EScSG activity index was observed, in line with the significant improvement of the mRSS and the stabilisation of internal organ involvement. To our knowledge, this is the first study to attest sensitivity to change of the EScSG activity index in the subset of 'early' dcSSc. ClinicalTrials.gov Registration, http://clinicaltrials.gov, number NCT00379431.